Stockwinners Market Radar for October 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:15 EDT Roivant Sciences director sells $79.7M in common stock - In a regulatory filing, Roivant Sciences disclosed that its director Keith Manchester sold 6.9M shares of common stock on September 28th in a total transaction size of $79.7M.

21:10 EDT Nuvei opens new office in China - Nuvei Corporation announces it has opened its latest operational hub in China as it continues to expand its presence in the Asia-Pacific region. CEO Philip Fayer stated: "We're thrilled to add an office in China to our global footprint as we continue to build our services in APAC. Ecommerce businesses rely on payments partners with global reach as well as local market expertise when they scale internationally. Our increased presence will enable businesses in APAC to enter new markets as we build on our existing regional expertise."

20:19 EDT Cathie Wood's ARK Investment bought 452K shares of Recursion Pharmaceuticals

19:52 EDT Trade Desk CEO sells $17.55M in common stock as part of option expiry - In a regulatory filing, Trade Desk disclosed that its CEO Jeffrey Green sold 225K shares of common stock on September 28th as part of option expiry in a transaction size of $17.55M.

18:22 EDT ALX Oncology to hold investor call on interim phase 2 ASPEN-06 trial data - ALX Oncology "announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer." Shares of ALX Oncology are up 21.2% afterhours at $5.83.

18:14 EDT Oddity expects to top Q3 revenue guidance - CFO Lindsay Mann says: "Our excellent third quarter performance and our momentum entering the fourth quarter give us confidence in our ability to deliver a strong finish to the year. We achieved high quality revenue upside at attractive margins, allowing us to beat our third quarter guidance. We now expect our year-over-year net revenue growth for the third quarter to be between 29%-31%, ahead of our initial guidance of 18%-23%. We expect gross margin of 68.5% approximately 100 basis points higher than our 67.5% initial guidance. We expect adjusted EBITDA margin of between 21.0%-21.5%, at the high end of our 20.0%-21.5% initial guidance. We plan to provide a full update to our full year earnings outlook when we report our third quarter results in November."

17:35 EDT MSP Recovery director buys $1.5M in common stock - In a regulatory filing, MSP Recovery disclosed that its director Frank Quesada bought 6.9M shares of common stock on September 29th in a total transaction size of $1.5M.

17:31 EDT Algoma Steel extends iron ore purchase contract with U.S. Steel - Algoma Steel Group (ASTL) announced a two-year extension of its existing iron ore purchase contract with United States Steel (X), with an option to further extend for a third year solely at Algoma's discretion. The extended purchase contract is anticipated to cover the expected volumes of iron ore required to complete Algoma's transition from blast furnace to electric arc furnace steelmaking. The extension with U. S. Steel represents another strategic milestone for Algoma as it continues on its transformative journey toward sustainable steel production through electric arc steelmaking.

17:07 EDT Athersys appoints Jane Wasman as board chair - Athersys announced changes to its board of directors following the company's recent 2023 annual meeting of stockholders. Current director Jane Wasman, has been appointed board chair, effective September 28. Wasman has served as a director of the company since November 2020, currently serving as chair of Athersys' audit committee and previously serving as chair of its nominations, governance and compliance committee. Wasman is founder and president of JWasman Advisors, a consulting firm focused on strategic, operational and corporate governance matters for biopharma and life sciences organizations.

17:00 EDT Jianpu Technology receives NYSE non-compliance letter - Jianpu Technology announced that it has received a letter from the New York Stock Exchange dated September 28, 2023, notifying the company that (i) it is below compliance standards due to the trading price of company's American depositary shares and (ii) the applicable cure period for the company to regain compliance expires on March 28, 2024. Pursuant to NYSE rule 802.01C, a company will be considered to be below compliance standards if the average closing price of a security as reported on the consolidated tape is less than $1.00 over a consecutive 30 trading-day period. Once notified, the company must bring its share price and average share price back above $1.00 within the applicable cure period following receipt of the notification. The company can regain compliance at any time during the cure period if on the last trading day of any calendar month during the cure period the company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that at the expiration of the cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures.

16:51 EDT Adeia enters long-term IP license renewal with Samsung for mobile devices - Adeia (ADEA) announced that Samsung Electronics (SSNLF) entered into a long-term agreement at the end of the third quarter, renewing its license to Adeia's media intellectual property portfolio for its mobile devices and related offerings.

16:42 EDT Sonendo discloses NYSE notice of listing non-compliance - Sonendo "announced that on September 28, 2023, it received notice from the New York Stock Exchange that the Company is not in compliance with applicable price criteria in the NYSE's continued listing standard set forth in the NYSE Listed Company Manual because the average closing price of the Company's common stock, par value $0.001 per share, was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company's common stock from the NYSE."

16:38 EDT Coty director buys $5.4M in common stock - In a regulatory filing, Coty disclosed that its director Maria Aramburuzabala bought 500K shares of common stock on September 28 in a total transaction size of $5.4M. Shares of Coty are up 3.5% afterhours at $11.12.

16:31 EDT Takeda to work with FDA toward voluntary withdrawal of EXKIVITY - The company states: "Takeda announced that, following discussions with the U.S. Food and Drug Administration, it will be working with the FDA towards a voluntary withdrawal of EXKIVITY, or mobocertinib, in the U.S. for adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy. Takeda intends to similarly initiate voluntary withdrawal globally where EXKIVITY is approved and is working with regulators in other countries where it is currently available on next steps. This decision was based on the outcome of the Phase 3 EXCLAIM-2 confirmatory trial, which did not meet its primary endpoint and thus did not fulfill the confirmatory data requirements of the Accelerated Approval granted by the U.S. FDA nor the conditional marketing approvals granted in other countries."

16:18 EDT Green Brick completes corporate headquarters move to Texas - Green Brick announced that the company has completed the move of its corporate headquarters to the Legacy office park in Plano, Texas. The move stems from the company's continued growth and reflects its commitment to better serve its homebuyers, builder brands, trade partners, and employees. The headquarters is home to Green Brick's corporate office as well as operations suites for CB JENI Homes, Normandy Homes, Southgate Homes, and Trophy Signature Homes. The building also includes separate office suites for Green Brick Title and BHome Mortgage.

16:16 EDT Leafly regains compliance with Nasdaq listing requirements - Leafly Holdings announced that on September 29, 2023, it received formal notice from The Nasdaq Stock Market LLC confirming Leafly has regained compliance with the minimum bid price rule set forth in Nasdaq Listing Rule 5550(a)(2).

16:14 EDT Atai Life Sciences completes VLS-01 study - Atai Life Sciences announced the completion of the Phase 1 study of VLS-01 in healthy participants. VLS-01 was well-tolerated with a favorable safety profile, and dose-dependent increases in exposure were observed. VLS-01 administration also resulted in subjective effects in most participants across doses. The company observed that participants that received 160mg of VLS-01 with a backing layer via buccal administration experienced the most robust and consistent increases in exposure and subjective effects compared to the other OTF cohorts, with results comparable to those seen in the IV cohort of DMT. The company now plans to progress VLS-01 into a Phase 1b study in healthy participants. The study is expected to explore doses up to 160 mg with an optimized OTF formulation that incorporates taste masking, an intrinsic backing layer, and enhancements designed to increase permeability, with goals of further improving the participant experience and pharmacokinetics. The company has submitted a protocol to regulatory authorities and expects to enroll the first participant in a Phase 1b study in the first half of 2024.

16:12 EDT Staffing 360 Solutions Board adopts stockholder rights plan - Staffing 360 Solutions announced that its Board of Directors has adopted a limited duration stockholder rights plan.The adoption of the Rights Plan is intended to protect the long-term interests of the Company and all of the Company's stockholders and enable them to realize the full potential value of their investment in the Company. The Rights Plan is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over, the Company through the open-market accumulation of the Company's shares without appropriately compensating all of the Company's stockholders for control. The Rights Plan is not intended to prevent or interfere with any action with respect to the Company that the Board determines to be in the best interests of the Company and its stockholders. Instead, it will position the Board to fulfill its fiduciary duties on behalf of all stockholders by ensuring that the Board has sufficient time to make informed judgments about any attempts to control or significantly influence the Company. The Rights Plan will encourage anyone seeking to gain a significant interest in the Company to negotiate directly with the Board prior to attempting to control or significantly influence the Company

16:10 EDT Symbotic announces CFO Tom Ernst to retire, Carol Hibbard to succeed - Symbotic announced that Tom Ernst will retire from his role as Chief Financial Officer CFO at the end of the calendar year. Carol Hibbard has been named to succeed Ernst as CFO upon his retirement and will serve as a member of the company's executive leadership team, reporting directly to Rick Cohen, Chairman of the Board and Chief Executive Officer.

16:09 EDT Avita Medical discloses FDA request for additional information on RECELL GO - In a regulatory filing earlier this morning, the company stated: "As previously disclosed, on June 30, 2023, AVITA Medical submitted a premarket approval supplement application to the FDA for its latest device, RECELL GO. The submission initiated a prioritized, interactive review of the PMA under the FDA's Breakthrough Device program, which follows a 180-day review cycle. At the halfway point of the process, the Company received notice from the FDA that additional information regarding the PMA is required for the continuation of a substantive review. This request, which is not unique to the Breakthrough Device Program, places the application file on hold for approximately 4 to 6 months while the Company addresses the FDA's questions. Upon the Company's submission of a complete response to the FDA's request, the application will reenter the 180-day cycle, with 90 days remaining in the review period. This timing would imply a product launch between May 1 and July 1, 2024." Shares of Avita Medical ended the day down 26% at $10.80.

16:07 EDT Bruker announces release of Hysitron TI 990 TriboIndenter - The company states: "At the annual Materials Science and Technology conference, Bruker Corporation announced the release of the Hysitron TI 990 TriboIndenter(R), which brings superior levels of performance, automation, and productivity to nanomechanical testing. TI 990 is a comprehensive advancement of Bruker's industry-leading TriboIndenter platform with new measurement modes, 2X faster testing throughput, and a larger 200mm x 300mm testing area. These enhancements deliver tangible benefits across a variety of applications and markets, for example, improved accuracy for nanoscale testing of polymer thin films, increased throughput for combinatorial materials science, and multi-measurement analysis of full 300-mm semiconductor wafers. With its combination of performance, usability, and flexibility, TI 990 is an ideal characterization solution for polymer research, alloy development, and semiconductor devices."

16:06 EDT Delta Apparel receives unsolicited offer to purchase its Salt Life business - Delta Apparel announced that it has received an unsolicited offer to purchase its Salt Life business unit and its board of directors has engaged Baird as the company's financial advisor. Bob Humphreys, Chairman and Chief Executive Officer, commented, "Our Board of Directors and management team are committed to maximizing value for Delta Apparel shareholders, and we believe it is in their best interests to conduct a thorough review of strategic options for our Salt Life business given the widespread interest in it. The Salt Life team has done an excellent job in taking what was essentially a small regional brand with a primarily wholesale business when we acquired it in 2013 and growing it into a highly profitable business with over $60 million in revenue, a consumer base stretching across the United States and internationally, and a variety of new go-to-market strategies, product categories and revenue channels. Today, Salt Life products are offered in over 1,700 wholesale doors across 48 states and direct-to-consumer via a growing eCommerce site as well as 25 branded retail stores spanning the U.S. coastline from California to Florida to New York."

16:05 EDT Visa launches $100M generative AI ventures initiative - Visa announced a new $100M generative AI ventures initiative to invest in the next generation of companies focused on developing generative AI technologies and applications that will impact the future of commerce and payments. As a pioneer of AI use in payments since 1993, Visa considers this initiative an extension of Visa's leadership in using AI to drive innovation in payments, create value for partners and clients, and enable and empower global commerce. Generative AI is an emerging subset of AI that is built on Large Language Models to develop artificial general intelligence capable of generating text, images or other content from large sets of existing data when given prompts. "While much of generative AI so far has been focused on tasks and content creation, this technology will soon not only reshape how we live and work, but it will also meaningfully change commerce in ways we need to understand," said Jack Forestell, Chief Product and Strategy Officer, Visa Inc.

16:04 EDT Bank OZK boosts dividend 2.78% to 37c per share - Bank OZK announced its Board of Directors declared a quarterly cash dividend on the Bank's common stock of 37c per share, up 1c, or 2.78% from the prior quarter. The common stock dividend is payable on October 20 to shareholders of record as of October 13. Bank OZK has increased its quarterly cash dividend on its common stock in each of the last fifty-three quarters.

16:02 EDT Brown-Forman board approves $400M buyback - Brown-Forman announced that its Board of Directors has approved a $400M share repurchase authorization, commencing October 2, 2023, through October 1, 2024, subject to market and other conditions. Under the repurchase program, the company can repurchase Class A and Class B common shares for cash in open market purchases, block transactions, purchases made in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and privately negotiated transactions, in accordance with applicable laws and regulations. This share repurchase program does not obligate the company to repurchase a minimum number of shares of Class A or Class B common stock, and this share repurchase program may be modified, suspended, or terminated by the company at any time without prior notice.

16:01 EDT MongoDB names Jim Scharf as Chief Technology Officer - MongoDB (MDB) announced Jim Scharf has joined the company as Chief Technology Officer. Scharf will lead MongoDB's global engineering organization, partner with other senior leaders to set and execute the company's technical vision and strategy, and oversee the development and delivery of MongoDB's products and services. Scharf joins MongoDB after 17 years at Amazon Web Services (AMZN), where he helped drive years of rapid growth and scaled product management, software engineering, security, operations, and solutions architecture organizations behind a number of successful products and services

13:19 EDT Praxis CEO says early efficacy data for PRAX-222 'especially exciting' - Praxis Precision Medicines provided an update on its clinical portfolio at the company's R&D Day. In conjunction with the event, Marcio Souza, president and CEO of Praxis, stated: "We were thrilled to be able to share important updates from our portfolio. Especially exciting is the early efficacy data we have seen with our PRAX-222 program in SCN2A gain-of-function developmental epilepsies and encephalopathies. Additionally, we are well on our way to initiate our Essential3 program in essential tremor this quarter and have been very encouraged by the early response from the community about participating in these trials." As of the cutoff date, EMBRAVE study data was evaluable for three of four dosing periods showing: Patients achieved a 44% median reduction in seizures versus baseline, on top of best available standard of care; Patients observed an increased number of days without seizures, achieving a median of 35% seizure free days over the dosing period compared to a baseline of 21% seizure free days; All patients achieved significant seizure reduction after one dose. Praxis said it intends to request a meeting in the fourth quarter of 2023 with the FDA to align on next steps for the PRAX-222 program.

12:16 EDT Interactive Brokers reports September DARTs down 8% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for September. Brokerage highlights for the month included: 1.798 million Daily Average Revenue Trades, 8% lower than prior year and 7% lower than prior month. Ending client equity of $369.8B, 29% higher than prior year and 2% lower than prior month. Ending client margin loan balances of $43.6B, 8% higher than prior year and 4% higher than prior month. Ending client credit balances of $98B, including $3.4B in insured bank deposit sweeps, 3% higher than prior year and 1% lower than prior month. 2.43 million client accounts, 21% higher than prior year and 3% higher than prior month. 168 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.21 including exchange, clearing and regulatory fees.

12:00 EDT Danaher falls -14.7% - Danaher is down -14.7%, or -$36.41 to $211.69.

12:00 EDT Aramark falls -27.5% - Aramark is down -27.5%, or -$9.55 to $25.15.

12:00 EDT a.k.a. Brands rises 1112.9% - a.k.a. Brands is up 1112.9%, or $4.84 to $5.28.

11:56 EDT Alexion treatment of transthyretin amyloidosis granted FDA orphan status - Alexion Pharmaceuticals' recombinant human anti-ATTR-immunoglobulin G1 monoclonal antibody was granted FDA orphan designation as a treatment of transthyretin amyloidosis, according to a post to the agency's website. Reference Link

11:16 EDT JAS Worldwide selects Zebra's Robotics Automation solution - Zebra Technologies announced JAS Worldwide has selected Zebra's Robotics Automation solution to drive efficiency in its fulfillment operations. Zebra's CartConnect100 autonomous mobile robots support JAS Worldwide's strategy to increase throughput for its fulfillment customers at its new 300,000 square-foot Contract Logistics Super Hub in Olive Branch, Mississippi.

11:14 EDT Novo Nordisk announces FDA approval of Rivfloza injection for PH1 - Novo Nordisk announced that the U.S. FDA has approved Rivfloza injection 80 mg, 128 mg, or 160 mg, a once-monthly subcutaneous ribonucleic acid interference therapy, to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 and relatively preserved kidney function. "The FDA approval of Rivfloza builds on Novo Nordisk's legacy of advancing research, fostering innovation and creating strategic partnerships to expand treatment options in rare diseases," said Blandine Lacroix, Senior Vice President, Strategy and Rare Disease at Novo Nordisk Inc. This approval is based on the results of the pivotal phase 2 PHYOX 2 clinical trial and interim data from the ongoing phase 3 PHYOX 3 extension study. PHYOX 2 met its primary endpoint, showing that patients treated with Rivfloza achieved a marked reduction from baseline in 24 hour-urinary oxalate excretion from Day 90 to Day 180.

10:20 EDT Vericity Inc trading resumes

10:12 EDT Northwest Natural, Hycamite explore opportunities for hydrogen production tech - NW Natural and Finland-based Hycamite TCD Technologies have signed a letter of intent to explore applications for Hycamite's novel methane pyrolysis technology to produce and distribute clean hydrogen. Within NW Natural's service territory, large natural gas customers could develop facilities that use Hycamite's novel methane-splitting technology to deliver low-carbon hydrogen to supplement or replace natural gas usage. Hycamite would install, commission, operate and maintain the methane pyrolysis units while NW Natural would deliver the natural gas feedstock used to produce hydrogen.

10:06 EDT Enlight Renewable secures PPA for Pupin wind farm in Serbia - Enlight Renewable Energy has been awarded a 15-year inflation-linked power purchase agreement for the Company's Pupin wind farm in Serbia. Under the PPA, the state-owned utility Elektroprivreda Srbije will purchase 72% of the project's output at a price of EUR 69 per MWh linked to Eurostat's Consumer Price Index. The remainder of the electricity produced will be sold on a merchant basis. With a total generation capacity of 94 megawatts, the Pupin project will cost $149-157 million, and is expected to generate revenues of USD$22-24 million and EBITDA of $13-15 million in its first full year of operation. Enlight has recently signed a binding agreement to acquire a 66% stake in the project from its partners, which is subject to approval by the Serbian regulator. The Company will own 100% of the project after completion of the acquisition. Construction of the Pupin wind farm began in the second quarter of 2023, post the realization of a turbine supply agreement with Nordex. Upon execution of the PPA, Enlight will have completed all development milestones of the project. Pupin is expected to reach commercial operation in the second half of 2025. Pupin is located adjacent to Blacksmith, Enlight's first wind farm located in Serbia with a capacity of 105 megawatts and operational since July 2019. Both projects will share the same connection point to the national grid. This highlights yet again Enlight's ability to execute on its "Land and Expand" strategy, utilizing the Company's deep understanding of interconnection infrastructure to deliver high conversion of its development portfolio.

10:00 EDT Danaher falls -13.1% - Danaher is down -13.1%, or -$32.58 to $215.52.

10:00 EDT Aramark falls -28.7% - Aramark is down -28.7%, or -$9.95 to $24.75.

10:00 EDT a.k.a. Brands rises 985.3% - a.k.a. Brands is up 985.3%, or $4.29 to $4.72.

09:52 EDT Sigma Lithium announes production of 890 tonnes per day at Greentech Plant - Sigma Lithium Corporation announced that its Greentech Plant has reached record daily peak production of 890 tonnes, equivalent to annualized production of 320,000 tonnes of Triple Zero Green Lithium at battery grade with 5.5% of lithium oxide. Therefore, as planned, the company demonstrates it remains on track to achieve annual 2023 production guidance of 130,000 tonnes of Triple Zero Green Lithium.

09:47 EDT Danaher falls -11.1% - Danaher is down -11.1%, or -$27.58 to $220.52.

09:47 EDT Armour Residential REIT rises 394.4% - Armour Residential REIT is up 394.4%, or $16.76 to $21.01.

09:47 EDT Skillsoft rises 1829.2% - Skillsoft is up 1829.2%, or $16.21 to $17.10.

09:27 EDT Renovaro CEO 'optimistic about growth trajectory' for combined company - CEO Mark Dybul said, in part, "I am writing to provide you with an update on our recent news of signing a definitive agreement to combine with GEDiCube and to share our vision for the promising future of our newly combined company if you, as shareholders, approve the agreement. As we embark on this next chapter, we want to express our appreciation for your ongoing support and investment. Renovaro Biosciences and GEDiCube strategically decided to combine our two companies just months ago. We believe the combination will accelerate our shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics. The parties intend that I will serve as the CEO of the combined company. I am humbled and honored to serve in that role. I firmly believe that we will achieve far more together than either company could on its own. GEDiCube spent over a decade developing a proprietary AI platform that has already shown accuracy in detecting cancers earlier through analysis of complex molecular data. Renovaro leveraged decades of collective immunology expertise to develop a robust pipeline of novel immunotherapies. By joining forces, our two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments. At the same time, we will maintain nimble independent operations, allowing each platform to advance rapidly. I am excited to lead this combined company alongside our esteemed leadership team and board members, who offer unparalleled experience across AI, healthcare, and biotechnology. We share an ambitious vision to leverage AI to improve patient outcomes by detecting diseases sooner and matching treatments more precisely to the individual. We believe that the coming months will be exciting as we prepare to realize this combination's potential and deliver on our commitment to shareholders...I am optimistic about the growth trajectory ahead for our combined company, with multiple revenue-generating products expected to begin in 2024. The AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024. The rapidly expanding precision medicine market - which is projected to reach $175 billion by 2030 - represents a tremendous opportunity. We believe we are strategically positioned to capture a substantial share of a largely untapped market. The immunotherapy division plans to start Phase 1/2 trials of our lead asset in the second half of 2024. I believe that this breakthrough approach could possibly lead to emergency use authorization as soon as the end of 2027 following the results of a Phase 2 clinical trial, transforming treatment for cancers with stagnant survival rates like pancreatic cancer. We are also focused on supplementing our cash position through dilutive and non-dilutive opportunities for pancreatic and other cancers, as well as for AI. I am confident in our future, defined by life-saving advancements in diagnostic insights and targeted immunotherapies for previously untreatable diseases."

09:18 EDT Marcus announces Beyonce concert to show at theatres - Beyonce plans to celebrate her sold-out Renaissance World Tour on the big screen at Marcus Theatres, a division of Marcus. The concert will show Thursdays, Fridays, Saturdays, and Sundays starting December 1, with special early screenings at 7:00 PM on November 30, at Marcus Theatres and Movie Tavern screens across 17 states. Individual tickets are on sale now, and fans who want to attend with their own hive can rent a private screening for 40 or more Beyonce devotees. The Renaissance World Tour kicked off in May, with over 2M fans experiencing it throughout the United States.

09:14 EDT Crown Electrokinetics commences work on purchase order - Crown Electrokinetics has commenced work on its first signed purchase order from its Arizona customer. While highly competitive bidding and contract award processes preclude Crown from naming the customer, they are one of the largest contractors in the United States with significant operations in Arizona and 19 other states. The Company will commence work today on this project, with this purchase order representing the first of what is expected to be many.

09:13 EDT EBET announces structral amendment, expansion of credit facility - EBET has amended its existing $30,000,000 Term Loan and increased borrowing availability by upsizing EBET's existing $2,000,000 discretionary Revolving Loan to $4,000,000 through a Second Amendment to Credit Agreement and an amendment to its existing Forbearance Agreement with CPBF Lending, its lender. The Amended Credit Agreements allow EBET to convert all interest expense from current cash pay to pay-in-kind additions to principal that will be due upon maturity, effectively deferring over $339,000 of monthly cash interest payments through the end of the forbearance period. The forbearance period has been extended from October 31, 2023 to June 30, 2025. The Amended Credit Agreements increase funds available to the Company under the discretionary Revolving Loan from $2,000,000 to $4,000,000. The interest rate on the Term Loan and the Revolving Loan has been increased from 15.0% to 16.5%. Outstanding principal and interest Term Loan and Revolving Loan amounts under the Amended Credit Agreements may be converted into EBET common shares at CPBF's option at a conversion price of $1.25 per share for the initial $5.0 million of the loan amount and at a conversion price of $2.50 per share for the remainder of the loan amount, provided that CPBF may not convert any portion of the loans into EBET common shares during an initial 45-day lockup or to the extent that, after giving effect to such conversion, CPBF and its affiliates would beneficially own more than 9.99% of the then issued and outstanding EBET common shares.

09:12 EDT Cassava Sciences completes patient enrollment for Phase 3 trial of simufilam - Cassava Sciences announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four Alzheimer's patients are enrolled in this 12-month trial. A second Phase 3 clinical trial with a target enrollment of approximately 1,100 patients is expected to complete patient enrollment in Q4 2023. Both on-going Phase 3 clinical trials are evaluating the safety and efficacy of oral simufilam in patients with Alzheimer's disease dementia.

09:11 EDT Coherus Biosciences announces support for Rare Cancer Day - Coherus BioSciences announced recognition and support for Rare Cancer Day to raise awareness for rare cancers such as nasopharyngeal carcinoma. "Rare cancers, such as NPC, affect under-served populations, and raising awareness among patients and the medical community is critical for early detection and treatment leading to improved survival rates," said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. "Patient advocacy groups, such as TargetCancer Foundation and NORD Rare Cancer Coalition, play an important role in raising awareness for rare cancers through their partnerships with the government and companies developing treatments to improve outcomes for patients." Additionally, Coherus recognizes the importance of and applauds the bipartisan Congressional resolution introduced in the U.S. House of Representatives on September 26, 2023.

09:09 EDT Tesla reports 435,059 vehicles delivered in Q3 - Tesla stated: "In the third quarter, we produced over 430,000 vehicles and delivered over 435,000 vehicles. A sequential decline in volumes was caused by planned downtimes for factory upgrades, as discussed on the most recent earnings call. Our 2023 volume target of around 1.8 million vehicles remains unchanged." The company reports deliveries of 435,059 vehicles and production of 430,488 vehicles. Reference Link

09:08 EDT Viatris agrees to divest Women's Healthcare unit, API unit in India

09:07 EDT Viatris announces agreements on remaining planned divestitures - Viatris announced it has received an offer for the divestiture of substantially all of its Over-the-Counter business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction. Viatris CEO Scott A. Smith said: "I am very excited about today's announcement as it marks an important milestone in the execution of our overall strategic plan. Not only will this bring to conclusion all of our Phase 1 commitments, including the expected achievement of our deleveraging target of 3 times gross leverage in the first half of 2024, importantly it will also set the company up extremely well as we enter into our Phase 2 strategy for 2024 and beyond. With this announcement the company has delivered on its commitment to announce agreements on all planned divestitures by the end of 2023 within the company's previously communicated range, after considering the estimated retained value. Including gross proceeds from the company's completed biosimilars divestiture, the company expects to realize gross proceeds representing a multiple above 12x on 2022 estimated Adjusted EBITDA for its portfolio of divested assets. The gross proceeds to the company from all divestitures under the terms of the agreements are up to $6.94B, or up to approximately $5.2B in estimated aggregate net proceeds, taking into consideration taxes and other costs, including related transaction costs. The company made the strategic decision to retain rights for Viagra, Dymista, and select OTC products in certain markets representing estimated retained value of approximately $1.6B applying the OTC multiple of 12.8x to the 2022 estimated Adjusted EBITDA of $125M attributable to the retained business. Total gross proceeds from all planned divestitures and estimated retained value are in line with the company's previously communicated range. Viatris intends to prioritize the use of net proceeds from the divestitures for debt paydown. The application of such proceeds is expected to achieve a gross leverage target of 3.0x in the first half of 2024, completing all Viatris' Phase 1 commitments which the company believes will position it to accelerate growth and increase shareholder return as it enters Phase 2 of its strategic plan in 2024. In addition, the company expects that completing the divestitures would substantially simplify the organization. Under the terms of the today's announced divestitures, up to12 facilities and more than 6,000 employees, representing 15% of the company's global workforce, may be conveyed. Viatris has received an offer from Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor. Viatris has executed an agreement to divest its API business in India to Iquest Enterprises, a privately held pharmaceutical company, also based in India. Viatris has also executed an agreement to divest its Women's Healthcare business, primarily related to oral and injectable contraceptives, to Insud Pharma, a Spanish multinational pharmaceutical company. Separately, in another transaction, Viatris entered into an agreement to divest its rights to women's healthcare products Duphaston and Femoston to Theramex, a leading global specialty pharmaceutical company dedicated to women's health. The transaction is expected to close in Q4 2023. Viatris has also executed agreements to divest commercialization rights in certain non-core markets that were part of the combination with Upjohn in which the Company had no established infrastructure prior to or following the transaction. These transactions are expected to be completed in Q4 2023.

09:05 EDT Gannett and Jackpocket announce exclusive agreement - Gannett and the USA TODAY Network announced a multi-year agreement to become the official media partner of Jackpocket, America's #1 lottery app*. As the exclusive digital lottery courier of the USA TODAY Network, Jackpocket will reach a broad audience across the country and provide a fun and convenient way for the USA TODAY Network audience to order lottery tickets - right from their phones. "Partnering with Jackpocket as Gannett's official digital lottery courier will leverage the synergies between our mutual audiences including our 45 million engaged sports fans," said Kate Gutman, Gannett Senior Vice President of Content Ventures. "Given our reach and authority across the U.S., we hope to introduce Jackpocket as a simple and fun way to order official state lottery tickets from the comfort of home or on a device."

09:04 EDT Sermonix announces results from ELAINE-1 trial of Ligand's Lasofoxifene - Sermonix Pharmaceuticals shared the results of an exploratory analysis evaluating the effects of patient characteristics on baseline vaginal/vulvar symptoms during its Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations study. The findings were shared Sept. 28 in a poster presentation at The Menopause Society 2023 Annual Meeting. Assessing a limited number of patients with ER+/HER2- breast cancer, results showed that younger age, non-visceral disease, prior tamoxifen, and a longer total duration of aromatase inhibitor use in the adjuvant or metastatic settings may be associated with higher baseline vaginal and/or vulvar symptomatology. Patients had more severe vaginal/vulvar symptoms if they were under age 40 versus patients over 40, and if they did not have visceral disease compared with those who had visceral disease. Prior adjuvant tamoxifen was associated with more severe vaginal/vulvar symptoms, as was a longer total duration of AI use in both adjuvant and metastatic settings. Duration of prior AI in the adjuvant setting alone did not impact baseline vaginal or vulvar symptoms. Sermonix licensed Lasofoxifene globally from Ligand Pharmaceuticals

09:03 EDT Rapid7 expands endpoint protection capabilities for MDR service - Rapid7 announced that its Managed Detection and Response service now includes multi-layered endpoint prevention and forensics capabilities powered by its Insight Agent. The Insight Agent already delivers powerful vulnerability scanning, high-efficacy threat detection, and swift containment activities. With the addition of next-generation antivirus and Velociraptor's digital forensics and incident response capabilities, customers will be able to further consolidate and maximize their investment by reducing complexity, increasing efficacy, and driving efficiency with core endpoint protection use cases.

09:02 EDT Broadcom announces availability of Sian BCM85822 - Broadcom announced the availability of its 5nm 200G/lane optical PAM-4 DSP PHY, the Sian BCM85822, at the 49th European Conference on Optical Communication. The BCM85822 features 200G/lane serial optical interfaces, which enable optical transceiver manufacturers to cost effectively deliver 800G and 1.6T pluggable modules and meet the growing bandwidth needs and low power consumption requirements of hyperscale data centers.

08:45 EDT SGHC announces exit from India and reaffirms 2023 financial forecast - Super Group announced that it has ceased providing any services to the Indian market due to changes to the Indian Goods and Services Tax, effective as of October 1 The newly effective tax rules make the Indian market no longer commercially viable for Super Group. Despite this development, Super Group reaffirms the full year financial projections provided on the earnings conference call on August 17. Neal Menashe, Chief Executive Officer of Super Group, stated: "We are continuously evaluating evolving regulatory landscapes across the many markets we serve. Informed by years of operating our geographically diverse business, we remain confident about the long-term growth opportunities in front of us."

08:43 EDT Safe & Green announces non-binding LOI to sell Lago Vista Site for $11.5M - Safe & Green Holdings announced that a subsidiary of its real estate development subsidiary, Safe and Green Development Corporation has entered into a new non-binding letter of intent to sell its Lago Vista site for $11.5M, the proceeds of which will be invested as equity in a new joint venture with a premier real estate development firm. The two companies plan to co-develop the site using SG Echo's modular units. The Lago Vista property was initially acquired by the Company in 2021 for $3.5M. ..We are extremely pleased with the terms of this new LOI for the sale of our Lago Vista site," said David Villareal, President & CEO of Safe and Development Corporation. "As we have stated in the past, we believe there is tremendous potential in the Lago Vista property. The LOI contemplates an $11.5 million purchase price; however, we have elected to receive payment as equity in a joint venture to be formed with one of the region's leading real estate development firms, who will be responsible for funding development of the site. Together, the two companies will be responsible for developing the land, and it is expected that SG Echo will supply the modular units. In this way, we anticipate that Safe & Green Holdings will generate revenue from its manufacturing services, while both Safe & Green Holdings and SG DevCo will benefit from the anticipated appreciation of the property. This site, once developed, may include a hotel, luxury condos, and even a marina. Overall, we believe that the planned sale and joint venture represents the best possible outcome for both Safe & Green Holdings and SG DevCo, as well as the respective shareholders of both companies, showcasing our proficiency in optimizing and capitalizing on our strong asset base and manufacturing capabilities." The LOI is non-binding and subject to a number of conditions, including execution of a final purchase and sale agreement and establishment of the joint venture. After execution of a final purchase and sale agreement, the buyer will have an initial 150 day feasibility period, which may be extended, to conduct surveys, assessments and other tests, during which the buyer can terminate the purchase and sale agreement in its sole discretion.

08:38 EDT Mirum: Primary endpoint in RESTORE study results was statistically significant - Mirum Pharmaceuticals announced positive data from the Phase 3 RESTORE study evaluating Chenodal, chenodiol tablets, in 13 adult patients with cerebrotendinous xanthomatosis, or CTX. The study objective was to evaluate the safety and efficacy of Chenodal by measurement of urine bile alcohols and other secondary measures. The primary endpoint of reduction in bile alcohols (urine 23S-pentol) was highly statistically significant . The difference between placebo and active Chenodal at the end of the randomized double-blind withdrawal period was 20-fold. In CTX, a deficiency of the bile acid CDCA leads to a buildup of bile alcohols which precedes a toxic accumulation of cholestanol..."The statistically significant reductions in bile alcohols and cholestanol underscore the potential for Chenodal to have a dramatic and meaningful impact on patients with CTX," said Chris Peetz, president and chief executive officer at Mirum. "This is an extraordinary outcome, and we look forward to moving quickly to submit these data to the FDA with the goal of broadening the impact of Chenodal for patients with CTX. " ...Data from the RESTORE study will be presented at an upcoming scientific congress, including forthcoming results from the open-label pediatric group of patients. In addition, Mirum will be submitting a new drug application to the U.S. FDA in the first half of 2024.

08:35 EDT Hoth Therapeutics granted Pre-IND meeting for HT-KIT by FDA - Hoth Therapeutics announced the Pre-IND meeting requested on September 8th for HT-KIT with the U.S. FDA has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the FDA. The Pre-IND meeting topics include the acceptability of the overall proposed drug development program for HT-KIT including requirements for nonclinical, clinical pharmacology, clinical, chemistry, and manufacturing controls. The proposed clinical trial designs for the first clinical studies in the HT-KIT program are also included in the Pre-IND meeting topics to receive FDA feedback.

08:34 EDT IperionX partners with GKN on titanium manufacturing - IperionX has agreed an order with GKN Aerospace for the delivery of titanium plate test components manufactured with IperionX's advanced titanium technologies. Titanium is a critical material for many aerospace systems and GKN Aerospace is a world leader in manufacturing complex titanium components for civil aerospace, space and military markets, including the Airbus A320/A330, Boeing B777/B787, Lockheed Martin F-16 and F-35 Lightning, and the Ariane 6 rocket engine. The collaboration with GKN Aerospace builds on the successful testing and validation of IperionX 100% recycled titanium powder made from GKN scrap titanium feedstocks. This latest commercial partnership focuses on the manufacturing of high-performance titanium plate for testing by GKN Aerospace, which may also form part of further collaboration efforts between GKN Aerospace and IperionX - including projects linked to the U.S. Department of Defense.

08:34 EDT Duck Creek Technologies extends partnership with Hyland as sponsor - Duck Creek Technologies extends support to ecosystem partner Hyland and sponsors its CommunityLIVE user conference, which takes place October 3-5, 2023 in Las Vegas, Nevada. Duck Creek continues to strengthen its customer focus by partnering with industry leaders, such as Hyland, and fulfilling its commitment to deliver more humanized technology experiences across the insurance industry. "Duck Creek is proud of our long-standing partnership with Hyland and our strong integration strategy, which allows us the opportunity to sponsor industry events such as CommunityLIVE," said Robert Fletcher, Sr. Partner Manager, Duck Creek Technologies. "Through meaningful integrations, we are able to bring further value to our customers with enhanced user experiences and operational efficiencies that take the burden off insurers."

08:32 EDT Mobiv Acquisition Corp provides update on planned SRIVARU merger - Mobiv Acquisition provided a business update regarding the planned merger with SRIVARU Holding Limited. Pursuant to the Merger Agreement, Mobiv plans to merge with and into Merger Sub, with Mobiv being the surviving company and a subsidiary of SRIVARU. Upon closing of business combination, Mobiv's common stock and warrants will convert into ordinary shares and warrants of SRIVARU. SRIVARU's ordinary shares and warrants are expected to begin trading on Nasdaq under the new ticker symbols "SVMH" and "SVMHW," respectively. The deadline for shareholders that have elected to redeem their Mobiv shares to reverse their redemption election is 3:00 pm Eastern Time on the day before closing. Shareholders that reverse their redemption by that deadline will be entitled to receive a pro-rata share of the additional 2,500,000 SRIVARU ordinary shares, to be issued as merger consideration in accordance with the amendment to the agreement and plan of merger with SRIVARU, as previously announced on August 9, 2023. In order for Mobiv public stockholders to receive a pro rata portion of the Bonus Pool Shares, they will need to be stockholders as of the closing of the merger and either not have elected to redeem their Mobiv shares or withdrawn their election to redeem by 3:00 pm Eastern Time on the day before closing.

08:31 EDT Greif acquires Reliance Products, terms not disclosed - Greif announced it has acquired Reliance Products, a producer of high-performance barrier and conventional blow molded jerrycans and small plastic containers in Canada. The all-cash transaction, which reflects approximately 6.75x proforma adjusted EBITDA, was funded through Greif's existing credit facility. The results of operations for Reliance will be reported within the Greif Global Industrial Packaging segment. Additional information on the acquisition and its expected impact on go-forward operations will be discussed as part of our 2023 fiscal fourth quarter earnings call scheduled for December 7, 2023.

08:22 EDT Amicus, Blackstone enter $430M strategic financing partnership - Amicus Therapeutics (FOLD) has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (BX). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus's common stock. The financing collaboration allows Amicus to grow revenues and move toward profitability while delivering on its mission for patients and its vision of being one of the leading biotechnology companies focused on rare diseases. Key features of this transaction include: $400M senior secured term loan facility; interest rate at adjusted Term SOFR plus 6.25%, subject to a 2.50% floor on Term SOFR; $30M investment in Amicus common stock; Requires interest-only payments until late 2026 and matures in October 2029; The full amount of the loan and equity purchase will be available and fully drawn at the initial funding; The proceeds will be used to refinance Amicus's existing debt and fund ongoing operations. Subject to completion of customary conditions, the loan is expected to be funded and the equity investment is expected to close on October 5, 2023.

08:20 EDT Siyata Mobile partners with Consort Digital in India - Siyata Mobile announced that Consort Digital PTE will offer its MCX ONE Push-to-Talk application on Siyata's SD7 handset.

08:19 EDT Veradigm, Holmusk invest to close evidence gap in behavioral health - Veradigm and Holmusk, a global behavioral health real-world evidence company, jointly announced the next stage in its strategic collaboration. The collaboration draws on the strengths of each company to fuel innovation in behavioral health and create the evidence needed to move the field forward. In this new phase of the collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk's NeuroBlu Database, a leading source for real-world data that shows how behavioral health care is delivered. Veradigm is also making an additional financial investment in Holmusk, building on a collaboration launched early this year, when Veradigm became the lead investor in Holmusk's Series B financing round. "This strategic investment represents significant growth for our NeuroBlu Database, enabling us to move closer to our vision of creating a single source of truth for behavioral health," said Nawal Roy, Holmusk's founder and CEO. "This is a crucial step as we work to help eliminate the gaps in evidence, information, and learning that have held the behavioral health industry back from moving to an outcome-based reimbursement system and a learning healthcare system." The collaboration expands Holmusk's NeuroBlu Database by millions of patients. The NeuroBlu Database will now be able to power even more research and address challenging behavioral health questions that require the creation of targeted research cohorts.

08:18 EDT KULR received a contract from top-5 American electric truck manufacturer - KULR Technology announced it has received a contract from a top-5 American electric truck manufacturer to develop newer and safer batteries for its next generation fleet of electric trucks and SUVs. By implementing the KULR ONE Design Solutions platform, KULR believes it can expedite the evolution to next generation electric trucks and SUVs anticipating safer EVs for consumers and faster growth for the Manufacturer. "We are proud to partner with another great American EV leader in utilizing KULR's proprietary, industry leading technology suite with the objective of making safer products for end users and unlocking substantial growth for another great company," commented KULR CEO Michael Mo. "We are excited to add to our base of tier one customers who could choose to work with anyone, but come to KULR for the critical solutions to meet exacting regulatory standards, deliver industry leading products, and grow their businesses for years to come."

08:17 EDT Enphase Energy launches IQ Combiner to streamline solar, battery installations - Enphase Energy announced the launch of the IQ Combiner 3P to dramatically improve the experience of installing an Enphase Energy System and deliver significant installation time savings. The IQ Combiner 3P is now available in nine European countries including Germany, Austria, Switzerland, the Netherlands, France, Belgium, Spain, Poland, and Portugal. The IQ Combiner 3P consolidates interconnection equipment into a single enclosure and streamlines solar and storage installations by providing a consistent, pre-wired solution for residential applications. With the new Enphase product, wiring time is significantly reduced through a simple and intuitive installation process. The IQ Combiner 3P includes the IQ Gateway Metered, two IQ Relays, a communications kit, two 4-pole circuit breakers, a residual current device, and supporting components pre-installed on a 3 DIN-rail assembly.

08:15 EDT Olympic Steel acquires Central Tube & Bar in immediately accretive deal,no terms - Olympic Steel announced that it has acquired Central Tube & Bar CTB . The all-cash purchase is expected to be immediately accretive. Terms were not disclosed. CTB was founded in 1996 and serves large original equipment manufacturers OEMs and fabricators across the Mid-South from three facilities in Conway, Arkansas, and Tulsa, Oklahoma, totaling 162,000 square feet of warehouse and production space. The business offers a range of value-added fabrication services, including tube laser cutting, tube bending, robotic welding, flat laser burning and brake press forming. CTB's trailing 12-month revenue for the period ended August 31, approximated $40M. "The acquisition of Central Tube & Bar represents our latest strategic move to invest in consistently high-performing businesses. We are delighted to welcome Dustin Ward and his capable team to the Olympic Steel family," said Richard T. Marabito, Chief Executive Officer. "Olympic Steel's tubular and pipe products segment has historically been our highest EBITDA-to-sales margin segment, and CTB's historical financial performance has consistently exceeded our tubular and pipe products returns. CTB is a well-run, growing organization, and a great cultural fit for Olympic Steel." Following the acquisition of CTB, Olympic Steel's total debt under its revolving credit facility is approximately $234 M with availability of approximately $359M leaving significant capital to continue its diversification strategy through investments in additional acquisitions, new capacity and increased efficiency through automation to deliver shareholder value.

08:13 EDT Ascendis Pharma presents TransCon PTH Data at ATA annual meeting - Ascendis Pharma presented a poster with results of a sub-analysis of its Phase 3 PaTHway clinical trial data during the recent American Thyroid Association, ATA, annual meeting, showing that 81% of adults with chronic post-surgical hypoparathyroidism treated with TransCon PTH achieved independence from conventional calcium and active vitamin D therapy while maintaining normal serum calcium levels during the 26-week blinded portion of the trial, compared to 6% taking placebo. The results were comparable to those from the overall PaTHway Trial population, which demonstrated consistency in improved outcomes with TransCon PTH treatment compared to conventional therapy across disease etiologies. "We are pleased to share with thyroid surgeons and thyroidologists attending ATA this data demonstrating the safety and benefits of TransCon PTH seen in clinical trial patients whose disease arose following neck surgeries," said Aimee Shu, M.D., Vice President of Clinical Development, Endocrinology Medical Sciences at Ascendis Pharma. "Our goal is to provide a treatment option that can help patients overcome the serious health and quality of life burdens associated with hypoparathyroidism, regardless of its cause. We will continue to advance TransCon PTH globally as a candidate to address the urgent needs of this patient community."

08:12 EDT Pulse teams with CardioNXT for nsPFA 1st in- human atrial fibrillation study - Pulse Biosciences announced a collaboration with CardioNXT, to support Pulse Biosciences' planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation. "We are excited to announce this collaboration and the progress we've made integrating our circumferential nsPFA catheter with the CardioNXT iMap System" "We are excited to announce this collaboration and the progress we've made integrating our circumferential nsPFA catheter with the CardioNXT iMap System," said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. "The CardioNXT navigation and mapping system was our top choice for integration with our novel nsPFA cardiac circumferential catheter. Their iMap system offers dynamic referencing to provide superior accuracy and stability when navigating our catheter to targeted tissue areas. We're on track to initiate our first-in-human study in the first half of next year and believe this combination has the potential to achieve best-in-class clinical outcomes."

08:11 EDT Pitney Bowes CEO Marc Lautenbach steps down, Jason Dies appointed interim CEO - Pitney Bowes announced that the independent members of its board of directors have unanimously approved the following actions: Jason Dies, who most recently served as the company's executive VP and group president, has been appointed interim CEO, effective immediately. The board will be conducting a search process for a new permanent CEO. The process will be supported by a nationally recognized, independent search firm. The process is expected to include internal and external candidates. In connection with these actions, Marc Lautenbach has stepped down as president and CEO and as a member of the board, effective immediately. With his departure, the company's board now includes eight members.

08:10 EDT Auddia releases new investor presentation - Auddia announced that it has released a new investor presentation. The new investor presentation incorporates several important content updates in addition to a general refresh of the look and feel of the slides to reflect the recent branding updates and new user interface the company introduced with the launch of faidr 3.0 earlier this year. The first meaningful content update brings the presentation current with the significant progress the Company has made in transitioning the product from faidr 1.0 to faidr 3.0 in 2023. The second meaningful content update adds an overview of the Company's strategy to use acquisitions as a complimentary path to exponentially grow the faidr 3.0 user base on both the free and subscription tiers.

08:10 EDT IceCure Medical's ProSense cryoablation validated in independent study - IceCure Medical, developer of the ProSense System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced that new data was presented at the European Society of Breast Imaging Scientific Meeting in Valencia, Spain by Lucia Grana-Lopez, MD, PhD, principal investigator of the independent, non-sponsored study. In a poster titled "Cryoablation for the treatment of early-stage breast cancer in patients who decline surgery" Dr. Grana-Lopez presented the findings of her study conducted at University Hospital Lucus Augusti in Lugo, Spain which used ProSense for cryoablation treatment of 31 patients with early-stage breast cancer who declined surgery, the standard of care. Dr. Grana-Lopez, a radiologist who specializes in breast and women's imaging, is Head of the Breast Unit at University Hospital Lucus Augusti. All patients were diagnosed with biopsy-proven early breast cancer with a median tumor size of 24 mm, ranging between 6 to 45 mm. Patients were followed by mammography and ultrasound every 6 months for 2 years and annually thereafter. The median follow-up was 10 months, with a range of 0 to 40 months. Cancer progression was observed in 1 patient. No major complications were seen and the procedure was well tolerated by all patients. The study concluded that cryoablation could be an alternative treatment to surgery for breast cancer in patients who reject surgery. Underscoring the need for such an alternative, the poster presented that breast cancer is the most commonly diagnosed malignant neoplasm worldwide and that while surgery is the standard of care for early-stage breast cancer, some patients, most of them elderly, decline standard of care surgery and prefer a less invasive option.

08:08 EDT Assembly Biosciences nominates ABI-6250 to progress to IND-enabling studies - Assembly Biosciences announced the selection of development candidate ABI-6250 to progress to IND-enabling studies. ABI-6250, an orally bioavailable small molecule entry inhibitor, is the first development candidate nominated by the company for the treatment of chronic hepatitis D virus infection, and the second development candidate selected in 2023, following ABI-5366 for high-recurrence genital herpes. "We're pleased to nominate ABI-6250 as a development candidate targeting chronic HDV infection, the most severe form of viral hepatitis," said William Delaney, PhD, chief scientific officer of Assembly Bio. "Current treatment options for HDV patients are limited and the only approved therapeutic requires daily injections. We are excited to bring ABI-6250 forward into IND-enabling studies with the goal of providing the first oral chronic therapy for HDV patients."

08:07 EDT Aemetis closes $53M sale of IRA tax credits - Aemetis closed the sale of $53 million of Inflation Reduction Act, IRA, investment tax credits generated by its subsidiary Aemetis Biogas to a corporate purchaser on September 29, 2023. This sale is the company's first IRA tax credit transaction. The Section 48 investment tax credits were generated from biogas projects built by Aemetis Biogas, including six diary digesters, a biogas pipeline and a renewable natural gas production facility. The Inflation Reduction Act was signed into law in August 2022, and provides for the issuance of transferable federal income tax credits for certain renewable fuel projects and products. "We believe that this $53 million tax credit sale is the largest IRA tax credit transaction in the dairy biogas industry, demonstrating the transferability of tax credits under the federal Inflation Reduction Act and the ability of renewable fuels projects to generate funding from IRA tax credits to support investments," stated Eric McAfee, Chairman and CEO of Aemetis. "The Aemetis Five Year Plan is expected to qualify for more than $800 million of IRA investment and production tax credits during the next four years to support our biogas projects, CO2 re-use by our ethanol plant, the construction of our sustainable aviation fuel plant and CO2 sequestration."

08:07 EDT Blackbaud extends existing stockholder rights plan - Blackbaud announced that its Board of Directors has unanimously approved an amendment to the company's existing stockholder rights plan, pursuant to which the expiration date has been extended from October 2, 2023 to October 2, 2024. All other terms and conditions of the Rights Plan previously adopted in October 2022 remain unchanged. The company expects to submit the amendment to the Rights Plan to the company's stockholders for ratification at the company's upcoming 2024 annual meeting of stockholders.

08:06 EDT Elys Game completes installation of North American hub infrastructure - Elys Game announced the successful installation of its North American server infrastructure located at the Continent 8 Data Center in Cincinnati, Ohio. The multimillion-dollar technology footprint establishes the hub of Elys' platform in Ohio and extends its network across multiple spokes throughout North America. Elys' technology hardware and database equipment serve as the backbone of the Company's mission-critical applications. The newly installed server infrastructure is equipped with intelligent storage, which allows autonomous operation to ensure predictable, scalable performance while delivering instant data access, all backed by a 100% availability guarantee. Meanwhile, the Company is working on obtaining regulatory approvals for the launch of tribal distribution in Michigan, North Dakota and New Mexico. Additionally, the Company plans to expand its non-tribal commercial operations in Washington D.C. and establish commercial operations in Ohio, Maryland and New Jersey. The Company is also exploring opportunities for future mobile operations in multiple U.S. states and Canadian provinces over the next six to eight months.

08:06 EDT Lowe's announces partnership with Carhartt - Lowe's and Carhartt, the uniform of hard work since 1889, announced a partnership that will bring an assortment of Carhartt products to Lowes.com and select stores nationwide. The collection will feature Carhartt's iconic duck jackets and vests, as well as hoodies, T-shirts, workwear pants and beanies. Currently, the collection is available at roughly 250 Lowe's stores across the Northeast, Midwest and Pacific Northwest - with approximately 250 additional stores in Texas, the Southeast and California adding Carhartt products in early 2024. Carhartt, known for producing gear designed to serve and protect hardworking people for more than 135 years, is popular among Pros and is committed to deepen its engagement with new audiences who will be the next generation continuing to build the workforce.

08:04 EDT PDS Biotechnology announces data on PDS0101 combined with chemoradiotherapy - PDS Biotechnology announced data demonstrating lead candidate PDS0101 in combination with standard-of-care chemoradiotherapy was associated with a rapid decline in human papillomavirus circulating cell-free DNA, a potential predictive biomarker of treatment response. The data from the IMMUNOCERV Phase 2 clinical trial were featured in an oral presentation by Aaron Seo, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the American Society for Radiation Oncology Annual Meeting in San Diego, CA. The IMMUNOCERV Phase 2 trial is investigating PDS0101 in combination with SOC CRT in the treatment of cervical cancer patients with large tumors over 5 cm in size and/or cancer that has spread to the lymph nodes. HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer. HPV type 16 is the most prominent subtype associated with cervical cancer. The study presented at ASTRO 2023 evaluated the relationship between the levels of circulating cfHPV-DNA and the extent of disease, clinical staging, and treatment response in patients with HPV-positive cervical cancer. Sixty-one patients with cervical cancer were included in the analysis either as part of a SOC treatment banking protocol or as part of the IMMUNOCERV Phase 2 clinical trial combining PDS0101 with SOC. Longitudinal plasma samples were collected from each patient at baseline, during weeks 1, 3, and 5, and at 3-4 months after CRT. In the study, HPV16 was detected in 59% of tumors and 70% of cfDNA. The median cfDNA at baseline was 28.15 copies/mL, with a range of 0 to 206,030 copies/mL. The presentation at ASTRO 2023 highlighted the following data: Earlier and greater proportion of cfDNA clearance with PDS0101 plus chemoradiation vs. SOC CRT alone. Baseline cfDNA levels correlated with the International Federation of Gynecology and Obstetrics stage and lymph node involvement; 100% of patients treated with PDS0101 had cancer that had spread to the lymph nodes

08:04 EDT American Electric names Charles Zebula as CFO, succeeding Ann Kelly - American Electric Power announced the appointment of Charles Zebula as executive vice president and CFO, effective immediately. Zebula previously served as AEP's executive vice president, Portfolio Optimization. He succeeds Ann Kelly, who is departing the company.

08:02 EDT Aadi Bioscience names Dave Lennon, Ph.D. as President and CEO - Aadi Bioscience announced the appointment of Dave Lennon, Ph.D. as President and CEO. Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases. Dr. Lennon has also joined the Aadi Bioscience Board of Directors. In connection with Dr. Lennon's appointment, Scott Giacobello, who served as Interim CEO and President since March 2023, will continue in his role as CFO.

08:01 EDT Spirit AeroSystems names Patrick Shanahan interim CEO - Spirit AeroSystems announced that Patrick Shanahan, a member of the company's Board of Directors, has been appointed interim President and CEO, effective immediately. Shanahan succeeds Thomas C. Gentile III as President and CEO. Gentile has resigned as a member of the Board, effective September 30, 2023. The company's Board will conduct a search to identify a new CEO.

07:39 EDT Rogers Communications turns on 5G service for TTC riders - Rogers Communications announced that it has turned on 5G service for transit riders in the busiest sections of the TTC subway system. To get the network ready for all riders on October 2, Rogers conducted extensive testing, including live calls with Toronto Maple Leafs Defenceman Morgan Rielly, who FaceTimed his father while riding the subway underground.

07:38 EDT Shyft signs agreement with Rush Enterprises for sales, service of Blue Arc - The Shyft Group (SHYF) announced it has finalized an agreement with Rush Enterprises (RUSHA), which operates the largest network of commercial vehicle dealerships in North America, to sell and service the Company's Blue Arc Class 3, 4 and 5 all-electric delivery vehicles. "When our customers couldn't find what they needed and asked us to enter the EV space for last mile delivery vehicles, we committed to deliver with commercial-grade quality, innovation, and a strong focus on driver needs," said Daryl Adams, President and CEO, The Shyft Group. "Doing so has enabled us to have outstanding partners and we could not be more pleased to have Rush Enterprises' support getting Blue Arc vehicles on the road across the country."

07:37 EDT CTO Realty Growth announces sale of single tenant office property in Virginia - CTO Realty Growth announced the closing of the sale of Reston Metro Center II, a 64,319 square foot single tenant office property located in Reston, Virginia leased to General Dynamics. The Property was sold for $18.5 million, representing an exit cap rate of 7.2% and generating a gain on sale of approximately $1.3 million. "This sale continues our progress of accretively recycling non-core assets into core retail shopping center properties in business-friendly growth markets," said John P. Albright, President and Chief Executive Officer off CTO Realty Growth, Inc.

07:35 EDT Zevra Therapeutics announces interim data from Phase 2 trial of KP1077 - Zevra Therapeutics announced interim data from the open-label dose titration phase of the Phase 2 clinical trial evaluating KP1077 in patients with idiopathic hypersomnia. The data provide valuable information on the primary endpoint of the trial, which is the safety and tolerability of KP1077 in patients with IH, as well as insights related to the effective dose range and regimen. Topline data from the completed trial are expected in the first half of 2024 after all patients have completed the double-blind withdrawal phase. The combined open-label interim and upcoming topline data are expected to also provide information related to a number of secondary and exploratory endpoints, including excessive daytime sleepiness, sleep inertia, and brain fog. The interim data related to the secondary and exploratory endpoints showed marked improvements in patient-reported assessments of key IH symptoms from the open-label titration phase, including excessive daytime sleepiness, sleep inertia, and brain fog. The improvements in symptoms were similar after both once-per-day dosing of KP1077, and twice-per-day dosing. The results from the completed Phase 2 trial are expected to inform the final design of the anticipated Phase 3 trial in IH, which is expected to be initiated by the end of 2024.

07:35 EDT Marimed announces results in Massachusetts brand equity study - MariMed announced Betty's Eddies and Nature's Heritage were the top two brands in terms of awareness in a study of Massachusetts cannabis brands conducted by leading market research company Brightfield Group. In a July 2023 brand equity study of 91 cannabis brands, Betty's Eddies fruit chews and Nature's Heritage flower and concentrates ranked #1 and #2, respectively, in brand awareness among non-retail product brands in Massachusetts. Additionally, the study found Betty's Eddies and Nature's Heritage scored an 8.6 and 8.5 out of 10 for product quality. The study also found that the brand awareness scores for all of MariMed's branded cannabis products, including Vibations and Bubby's Baked, increased among consumers since the last time the study was undertaken in December 2022. "It has been long understood that the most effective way to build brand equity in consumer products is through quality and brand awareness," said Ryan Crandal, MariMed's Chief Revenue Officer. "The results of Brightfield Group's cannabis brand equity study confirmed what we have always believed, which is that MariMed is arguably the only cannabis company that is building brands that will be the long-term winners in the industry. We could not be more thrilled that Massachusetts cannabis consumers recognize the quality and power of Betty's Eddies and Nature's Heritage. And for our Vibations and Bubby's brands to also be recognized after less than two years in existence, speaks volumes to our product development and marketing teams."

07:35 EDT Repligen appoints Loeillot as President, CCO - Repligen announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer, CCO effective immediately. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions.

07:33 EDT SL Green Realty launches sales at Giorgio Armani Residences - SL Green Realty in partnership with Giorgio Armani, announced that sales have commenced at 760 Madison Avenue, The Giorgio Armani Residences, their exclusive new development condominium project on the Gold Coast of Manhattan's Upper East Side, with only five of the ten residential apartments remaining available for purchase.

07:16 EDT Phoenix Motor signs non-binding convertible bond term sheet - Phoenix Motor announced that the Company has signed a non-binding convertible bond term sheet providing for up to $300 million in funding with a California-based investor to support the potential acquisition opportunity of commercial electric vehicle assets for which Phoenix has submitted an Indication of Interest. The Company expects to provide additional details regarding the potential acquisition only if and when a definitive agreement is executed. Completion of any financing or acquisition of assets is subject to, among other matters, the completion of due diligence, the negotiation of definitive agreements providing for the financing or acquisition, satisfaction of the conditions negotiated therein, including approval of the boards of both companies, as well as regulatory approvals. Accordingly, there can be no assurance that the parties will successfully negotiate and enter into a definitive agreement for the financing or acquisition, or that the financing or acquisition will be consummated on the terms or timeframe currently contemplated, or at all.

07:14 EDT Supremex appoints Paul Reilly to board of directors - Supremex announced the appointment of Mr. Paul V. Reilly as new independent director of the board of directors of the Company to fill a recent vacancy. Paul V. Reilly is a founder and partner at New Direction Partners since 2009.

07:13 EDT Agrify completes restatements of prior period results - Agrify Corporation announced that the Company has completed restatements of previously issued quarterly filings for the first three quarters of its 2022 fiscal year. The Company will file its Amended Forms 10-Q for the first, second, and third quarters of 2022 with the U.S. Securities and Exchange Commission. The Restatements primarily relate to warrants issued in January 2022 and March 2022 that were reclassified as liabilities rather than as equity, which requires the warrants to be remeasured each reporting period to present them at fair value. As previously announced, the Company also completed a 20 to 1 reverse stock split in July 2023, which is reflected in the restated Forms 10-Q on a retroactive basis. As expected, the Restatements did not impact the Company's cash position, business operation, or sales. The adjustments in the fair value of the warrants are non-cash items, but impacted earnings results. "The required adjustments were non-cash and had no impact on our business operations or the economics of our commercial arrangements," said Raymond Chang, Agrify's Chairman and Chief Executive Officer. "We appreciate the patience of our various stakeholders as we have worked to address the issues identified in our review of Agrify's historic financial results. We believe the review process undertaken is reflective of our diligent approach to ensuring the integrity of our financial statements and public filings. We continue to work hard to complete our 2022 Annual Report and 2023 Q1 Form 10-Q and 2023 Q2 Form 10-Q filings as expeditiously as possible and look forward to returning to business as usual going forward. As we look ahead, we remain committed to long-term value creation and executing on our mission to build out end-to-end solutions in the cannabis cultivation and extraction solutions industry in the United States and beyond. We remain cautiously optimistic about the growth trajectory of the business, and we thank our shareholders and other stakeholders for their patience as we work to complete this process."

07:12 EDT StateHouse, Stinson Brands enter strategic sales agency agreement - StateHouse announced that it has entered into a sales agency agreement with Stinson Brands, a management company that consults, and holds IP, for the development premium food and beverage brands with an emphasis on fine herbal tea blends. Under the terms of the strategic sales agency agreement, StateHouse will begin selling Stinson Brands products through its sales team and in its Harborside and Urbn Leaf dispensaries across California. StateHouse will work with its valued distribution partner, Nabis, to develop this new line of business, and expects to expand into new product categories while growing Stinson's well-known portfolio of brands including Kikoko, a cannabis botanical wellness company focused on offering women plant-based, scientifically proven alternatives to pharmaceuticals and alcohol, to new levels of success. "Kikoko is a top-selling California brand that continues to innovate its product offerings across multiple categories," said Ed Schmults, CEO of StateHouse. "StateHouse welcomes Kikoko to its roster of brands and believes this partnership will catapult Kikoko to new levels of visibility in the market while simultaneously fulfilling our promise to our patients and customers to provide the highest-quality cannabis products."

07:11 EDT Axsome Therapeutics joins National Alliance on Mental Illness - Axsome Therapeutics announced it is joining patient advocacy organizations, including the National Alliance on Mental Illness, to promote awareness of the importance of mental health during Mental Illness Awareness Week, recognized on Oct. 1-7, 2023. As part of Axsome's commitment to developing innovative therapies that make an impact on the lives of people suffering from CNS disorders including mental health conditions, Axsome supports and recognizes events such as MIAW to come together with other mental health advocates to amplify positive messages, share resources, and help raise awareness.

07:09 EDT ProFrac Holding evaluating strategic options for Proppant Production segment - ProFrac Holding announces that it is evaluating strategic options to maximize and realize the full value of its Proppant Production segment, which operates through its wholly-owned Alpine Silica subsidiary. A variety of options are under strategic review, including a public offering, a sale or merger of Alpine Silica and/or a potential recapitalization. In connection with its strategic review, the company also announces that entities affiliated with its largest shareholders, the Wilks Family, have invested $50M in perpetual convertible preferred equity securities issued by the company at a conversion price of $20.00 per share. Proceeds of the investment will primarily be used to reduce the company's indebtedness. No specific timeline has been established for the completion of the evaluation of strategic alternatives for Alpine Silica.

07:08 EDT Green Thumb Industries launches RYTHM Artist Series collection - Green Thumb Industries announced the launch of its RYTHM Artist Series, a collection of strains that are chosen by artists spanning multiple genres of music. Inspired by the artists' lifestyle and brand, each product aligns with their specific tastes, consumption preferences, and desired effects, and is complemented by its own unique strain name and packaging design. The RYTHM Artist Series will feature product launches by talented and passionate artists such as country music star Mitchell Tenpenny, pop-punk band State Champs, blues singer-songwriter Marcus King, and R&B and pop singer Tinashe.

07:08 EDT Wipro's Rizing, PlanSource announce partnership - PlanSource Benefits Administration announced that they and Rizing, a Wipro Company, have formed a partnership to deliver a leading-edge, personalized benefits experience for businesses using SAP SuccessFactors solutions. PlanSource is fully integrated with SAP SuccessFactors solutions, which creates a streamlined HR and benefits experience for employers and their employees. The partnership empowers Rizing to offer PlanSource to businesses using SAP SuccessFactors solutions that seek a highly configurable and innovative solution that can scale with growing businesses. "We are thrilled to partner with PlanSource and bring a leader in the benefits engagement and administration industry to our customers," said Derek Risley, Global VP of Sales and Business Development for the HCM line of business at Rizing. "With our years of experience in benefits administration and our knowledge of SAP platforms, this partnership will be extremely beneficial to our clients looking to simplify benefits administration with a fully integrated HR and Benefits platform."

07:07 EDT Trevena completes initial analysis of OLINVYK respiratory monitoring data - Trevena announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study. The VOLITION study, a real-world, open-label, multi-site study, assessed the potential impact of OLINVYK on respiratory, gastrointestinal, and cognitive function outcomes in the postoperative setting. The Company previously announced GI and cognition data from the study. VOLITION Study Data, Including Continuous Respiratory Monitoring Analysis, to be Presented at ASA in San Francisco from October 13-17, 2023. The Company has three abstracts accepted for presentation at ASA, which will be held in San Francisco from October 13-17. One abstract was selected for an oral presentation as a top research abstract. The oral presentation titled "Antinociception versus Neurocognitive Effect of Biased mu-Opioid Receptor Oliceridine versus Morphine: Utility Function Analyses" will be part of the Best of Abstracts: Clinical Science feature session. The abstracts are embargoed until the conclusion of the meeting and at which time they will be available at https://www.trevena.com/publications. Company to Participate in the BIO Investor Forum in San Francisco from October 17-18, 2023. Members of the Trevena management team will be participating in 1x1 meetings and encourage investors to schedule a time during the conference. VOLITION is a real-world, open-label, multi-site, post-approval clinical outcomes study in 203 adult patients undergoing major non-cardiac surgery. IV OLINVYK was dosed as the first-line analgesic during post-operative care, with a 1.5mg loading dose of OLINVYK at surgical closure, and 0.35mg to 0.5mg of OLINVYK, as needed, administered with a PCA device, with a 6-minute lockout period. Additional boluses of OLINVYK were available if needed as soon as 15 minutes after the initial 1.5 mg loading dose. Patients in the VOLITION study wore a device that continuously monitored physiologic status including heart rate, respiratory rate and indices of oxygen and expired carbon dioxide, with data from this monitoring collected in a manner blinded to the clinical staff caring for the patient. The continuous monitoring methods used in the VOLITION study were modeled after the similar methodology of respiratory depression assessment used in the recently completed PRODIGY study, which itself was led by clinical outcomes research experts from Wake Forest Baptist Health and the Cleveland Clinic. As in the PRODIGY study, investigators in the VOLITION study evaluated the proportion of patients meeting an expert adjudicated criterion of meaningful respiratory compromise, defined by a collapsed composite of any one or more of: end-tidal carbon dioxide less than15mmHg for greater than or equal to3 minutes; respiratory rate less than or equal to5 breaths/minute for greater than or equal to3 minutes; SpO2 less than or equal to 85% for greater than or equal to3 minutes; Apnea episode lasting greater than30 seconds; any serious respiratory event. No drug-related serious adverse events and no deaths were reported in the VOLITION study. The average age of patients in VOLITION was 57.1 years, with approximately equal representation of men and women. Approximately 86% of patients underwent an abdominal surgical intervention, such as partial or total colectomy, enterotomy or other open abdominal procedures. A majority of patients had significant morbidity at the time of surgery as reflected by ASA status, and their respiratory risk was intermediate to high risk, graded using the PRODIGY risk score. The average duration of the surgery was 4.8 hours.

07:07 EDT Tilray closes transaction acquiring eight brands from Anheuser-Busch - Tilray Brands (TLRY) announced that the Company has closed its all-cash previously-announced acquisition of eight beer and beverage brands from Anheuser-Busch (BUD), including the breweries and brewpubs associated with them. The acquired businesses include Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy. Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, said, "Tilray Brands' portfolio today reflects our diversified business and the integration of key strategic acquisitions that have enabled us to grow our top line and deliver substantial cost savings through synergies, all while significantly expanding distribution to coveted markets across the U.S. and internationally. With this EBITDA accretive transaction, Tilray has acquired a stellar lineup of eight craft beer and beverage brands that both solidify our leadership in the craft beer industry and strengthen our business in the expansive beverage sector in which we see tremendous opportunity to reinvigorate innovation across many categories including non-alcoholic beverages, energy, and nutritional drinks. Together with our best-in-class team, I am confident that we will successfully integrate our current beer assets with these newly acquired brands and businesses to set the stage for higher growth."

07:05 EDT Bitfarms mines 411 new bitcoin in September - Bitfarms provides a Bitcoin production and mining operations update for September 2023. "In September, we continued to install new miners and fully energized Rio Cuarto to 51 MW, increasing our operating capacity by 9% to 233 MW. Year-to-date, we increased operating capacity by 24% and upgraded and expanded our fleet with over 15,000 additional miners," said Geoff Morphy, CEO of Bitfarms. "Also in September, our hashrate increased 9% to 6.1 EH/s, slightly below our Q3 2023 target of 6.3 EH/s reflecting some electrical infrastructure delays that pushed out the Baie-Comeau, Quebec facility's full installation by a couple of weeks." September 2023 Select Operating Highlights: 6.1 EH/s online as of September 30, 2023, up 45% from September 30, 2022, and up 9% from August 31, 2023. 5.84 EH/s average online, up 13.7% from August 2023. 70.4 BTC/average EH/s, down 5.6% from 74.6 in August 2023. 411 BTC mined, up 7.3% from August 2023 and down 14.6% from September 2022. 13.7 BTC mined daily on average, equivalent to about $369,900 per day and approximately $11.1 million for the month based on a BTC price of $27,000 on September 30, 2023. Installed 4,600 miners. At Paso Pe, Paraguay, construction advanced as planned. At Rio Cuarto, Argentina: Increased capacity to full 51 MW and hashrate to 1.475 EH/s. At Baie-Comeau, Quebec: Remaining installations expected to ramp operating capacity to the full 11 MW in early October 2023.

07:04 EDT KKR sells over $560M of industrial real estate - KKR announced that KKR has completed the sale of over 5M square-feet of industrial warehouse and distribution properties for a total aggregate value of over $560M. The dispositions were completed through five discrete transactions with five separate buyers. The fifth and final sale closed on September 29th. The sales, primarily consisting of assets in KKR's Real Estate Partners Americas II fund, included over 50 industrial buildings located in high-growth, infill markets across Atlanta, Dallas-Fort Worth, Chicago, the Lehigh Valley and Central Pennsylvania. Since 2018, across its investment strategies in the U.S., KKR has acquired over 60M SF of logistics assets totaling approximately $8B of aggregate value. Including these five sales, KKR has sold approximately 21M SF since 2021 and currently owns over 40M SF of industrial real estate in major metropolitan areas.

07:03 EDT Cabaletta Bio receives FDA clearance of IND for CABA-201 - Cabaletta Bio announced that the Company's third Investigational New Drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been allowed to proceed by the U.S. Food and Drug Administration for a Phase 1/2 study in patients with systemic sclerosis. The Company plans to initiate a Phase 1/2 clinical trial of CABA-201 across two parallel SSc cohorts - one cohort of six patients with severe skin manifestations and a separate cohort of six patients with severe organ involvement associated with systemic sclerosis. Consistent with the previously announced CABA-201 IND clearances for lupus and myositis, the starting dose for the trial, 1 x 106 cells/kg, was informed by the high degree of similarity between CABA-201 and the CD19-CAR T construct administered to a patient with severe, diffuse SSc in the recent Annals of Rheumatic Diseases publication.

07:01 EDT Altair Engineering acquires OmniQuest, terms not disclosed - Altair acquired OmniQuest, a Novi, Mich.-based optimization software company. OmniQuest's flagship product, Genesis, is an advanced structural analysis and optimization software that uses the finite element method to solve problems with many variables and constraints.

06:57 EDT Arch Resources sees FY23 coking coal sales volume 8.6M-8.9M tons - Arch Resources announced that it now expects coking coal sales volumes for the third quarter to remain generally in line with those reported in the second quarter of 2023, due primarily to ongoing challenges mining in the first longwall district at its Leer South mine. In keeping with this revision to sales volume expectations, Arch is revising its full year 2023 guidance for coking coal sales volumes to 8.6 to 8.9 million tons and its average metallurgical cash cost guidance to $88 to $91 per ton.

06:54 EDT Timken acquires Rosa Sistemi, terms undisclosed - Timken has acquired Rosa Sistemi, a European designer and manufacturer of roller guideways, linear bearings, customized linear systems and actuators, commercialized ball guideways and precision ball screws. The company serves customers across end markets, including automation and machine tool. Rosa Sistemi is expected to generate around $15M in revenue in calendar year 2023. The company employs approximately 65 people and has its headquarters, R&D and manufacturing facility in Milan, Italy.

06:52 EDT ANI Pharmaceuticals: FDA approves 1-mL vial of Purified Cortrophin Gel - ANI Pharmaceuticals announced U.S. FDA approval and commercial availability of a 1-mL vial of Purified Cortrophin Gel. The 1-mL vial is now available via Cortrophin Gel's existing specialty pharmacy network and will also be available for ordering via national specialty distributors. Cortrophin Gel is already available in a 5-mL vial. Cortrophin Gel is indicated for short-term administration as an adjunctive therapy during an acute episode or exacerbation in acute gouty arthritis. Cortrophin Gel is contraindicated for intravenous administration. ANI reintroduced Cortrophin Gel to the market in January 2022. At that time, Cortrophin Gel became the first newly commercialized drug indicated for appropriate patients with acute gouty arthritis flares in 12 years. This smaller 1-mL product configuration was developed with the goal of helping enable rapid time to therapy, at point-of-care, for appropriate patients with acute gouty arthritis flares.

06:47 EDT iBio clarifies recent filing of registration statement - In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 filed on Friday, September 29, 2023 with the United States SEC, iBio provided the following clarification. The company filed a registration statement on Form S-3 (Registration No. 333-250973) declared effective by the SEC on December 7, 2020, which registered up to $200M of any combination of iBio's common stock, preferred stock, debt securities, warrants or units comprised of any of the foregoing securities of the Registrant. This Post-Effective Amendment was filed to convert the Original Registration Statement into a registration statement on Form S-1 in order to maintain the registration of certain common stock warrants issued and outstanding in connection with the company's December 2022 underwritten public offering, previously registered on the Original Registration Statement.

06:38 EDT Truist Financial announces board of director changes - Truist Financial announced changes to its board of directors. Four members of the board are retiring after reaching Truist's mandatory retirement age, and four members of the board have decided to conclude their board service, all effective December 31. With these changes, Truist's board will consist of 13 directors-12 of whom are independent.

06:37 EDT Stericycle announces additional project locations with National Park Foundation - Stericycle announced additional project locations as part of its five-year, $1M partnership with the National Park Foundation, which was initiated in 2021. Stericycle's commitment will support wetland restoration efforts at Yosemite National Park in California's Sierra Nevada mountains and Cape Cod National Seashore in Massachusetts. Prior commitments with the National Park Foundation helped rebuild oyster beds along identified coasts at the Timucuan Ecological and Historic Preserve in Jacksonville, Florida, as well as the Cumberland Island National Seashore in Saint Marys, Georgia, to help decrease erosion, improve water quality and restore ecosystems.

06:35 EDT Ault Inc. to sell multifamily development site in St. Petersburg, Florida - Ault Alliance announced its wholly owned subsidiary, Third Avenue Apartments, itself a wholly owned subsidiary of Ault Global Real Estate Equities, has listed for sale its multifamily development site in St. Petersburg, Florida. Third Avenue has signed a listing agreement with international brokerage firm CBRE.

06:31 EDT Trane to acquire Nuvolo, terms not disclosed - Trane Technologies announced that it has signed a definitive agreement to acquire Nuvolo, a global leader in modern, cloud-based connected workplace and enterprise asset management products and solutions. Nuvolo Founder and CEO Tom Stanford will join Trane Technologies in a leadership role and will continue to lead the Nuvolo business and team of approximately 250 global associates. The transaction is subject to regulatory approval, with closing expected in the fourth quarter of 2023.

06:05 EDT Hollysys announces formal sale process as part of strategic review - Hollysys announced the formation of a special committee of the board of directors of the company to conduct a formal sale process. This decision follows a review of various strategic options. As part of its work, the special committee will immediately engage in discussions as to next steps with Recco Control Technology and Dazheng Group Investment in response to the previously announced unsolicited, non-binding offer to acquire the company at $25.00 per share in cash. In parallel, the special committee will, with the assistance of the company's financial advisor, Deutsche Bank, begin an expedited process to solicit additional serious and compelling offers, with the aim of providing bidders with the opportunity to participate on a level playing field. The special committee will work to advance this process in an orderly and expeditious manner and will provide shareholders with timely material updates. Separately, the board has engaged with certain shareholders in response to the notices of intention to request a special meeting. If the board determines the required shareholding threshold to convene a special meeting has been met as of the demand record date of September 6, and such requests are accompanied by other materials required by the memorandum and articles of association of the company, the board will duly move forward to send notice of a special meeting to shareholders. The company is committed to taking actions in the best interests of shareholders and will continue to work with its financial and legal advisors to identify the best path forward for value creation. The board, in its assessment of the strategic options in furtherance of shareholder interests, cautions the shareholders and others considering trading the company's securities that no decisions have been made with respect to any strategic option that the company may pursue. There can be no assurance that any definitive offer will be received or that any definitive agreement will be executed relating to any transaction.

06:02 EDT MEI Pharma announces limited-duration stockholder rights plan - MEI Pharma announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances. The Board of Directors resolved to adopt the Rights Plan following the recent Schedule 13D amendments filed by Anson Advisors and Cable Car Capital LLC, in which the Anson and Cable Car Group disclosed that they and their affiliates have acquired a position that represents approximately 19.9% of the outstanding shares in MEI Pharma held outright. Additionally, the Anson and Cable Car Group have sold exchange-listed put options representing a potential aggregate of an additional 1.5M shares. Pursuant to the Rights Plan, the company is issuing one right for each share of common stock as of the close of business on October 12, 2023. The rights will initially trade with MEI Pharma's common stock and will become exercisable only if any person acquires 20% or more of the company's outstanding common stock. In that case, each holder of a right will be entitled to purchase, at the then-current exercise price, additional shares of common stock having a then-current market value of twice the exercise price of the right. Any stockholders with beneficial ownership of 20% or more of the company's outstanding common stock prior to this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan. The Rights Plan is effective immediately and will expire on September 30, 2024.

05:46 EDT Minerals Technologies announces subsidiaries file for Chapter 11 bankruptcy - Minerals Technologies announced that its subsidiaries, Barretts Minerals and Barretts Ventures Texas, filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas to address and resolve BMI's liabilities associated with talc. The debtors intend to operate their businesses normally throughout the duration of the Chapter 11 cases. No other subsidiaries or business units of MTI are included in the filing and, as such, all are operating business as usual and will continue to do so during and after the Chapter 11 process. BMI intends to pursue a sale of its talc assets under section 363 of the Bankruptcy Code. Proceeds of the sale will be used to fund the Chapter 11 case and an anticipated section 524(g) trust. To facilitate this process, the debtors have received a commitment of approximately $30M in debtor-in-possession financing, or DIP, from JMB Capital Partners Lending, which, subject to the Bankruptcy Court's approval, will provide sufficient liquidity to continue operations until the Debtors are able to access proceeds of the sale.

05:26 EDT DexCom announces new CGM data at EASD - DexCom announced new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6 in Hamburg, Germany. New results from the COMISAIR seven-year study, the longest prospective real-world CGM study ever conducted, show significant and continued reduction of HbA1c with the use of real-time CGM by people with Type 1 diabetes. Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years. The COMISAIR study also shows further substantial reduction in HbA1c when real-time CGM is connected to an automated insulin delivery system, specifically Tandem Control IQ. In addition, the study showed high CGM adherence over seven years, regardless of insulin delivery method, 88.8% for those using CGM and multiple daily injections and 91.9% for those using CGM and AID. Dexcom announced the Dexcom G7 CGM system will begin launching with the Tandem t:slim X2 insulin pump before the end of the year in the U.S. and multiple markets across Europe and Asia-Pacific. This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany. In addition to the successful results from the COMISAIR study, a new single site study shows use of the Dexcom ONE CGM system by people with both Type 1 and Type 2 diabetes on intensive or basal insulin leads to significant HbA1c reduction. The Dexcom ONE prospective study shows use of Dexcom ONE in Type 2 subjects reduced HbA1c from 10.1% to 8.5% over three months and further reduced HbA1c to 8.3% at six months. By funding and supporting new studies that explore the efficacy of real-time CGM among those with Type 2 diabetes, Dexcom is working to improve access and expand reimbursement for more people around the world, giving them the tools they need to improve their metabolic health, lead healthier lives and stop disease progression. A new study featured at EASD, shows Dexcom G7 is accurate overall during pregnancy and across all sensor wear days and all glucose ranges for pregnant women with Type 1, Type 2 and gestational diabetes. Dexcom G7 and Dexcom G6 are now the only commercially available CGM systems with clinical studies demonstrating real-time CGM is accurate when used by people with Type 1, Type 2 and gestational diabetes during pregnancy.

05:17 EDT EXL to establish headquarters for international business in Dublin - EXL announced it will establish a headquarters for international business in Dublin. EXL plans to hire up to 200 artificial intelligence, data engineers and other technology positions in Dublin over the next three years. This builds upon EXL's existing staff of more than 8,000 data scientists and 1,500 generative AI experts globally who are developing AI, cloud enablement and data integration technologies and continually introducing new technologies to the marketplace. EXL will also establish new global centers of excellence across its operation, to streamline management and enable the business to develop best practices to improve efficiencies and reduce costs. As part of its expansion into Ireland, EXL announced a new collaboration with University College Dublin, or UCD, one of Europe's research-intensive universities.

05:10 EDT InterDigital, IIT-K announce bilateral research partnership - InterDigital and the Indian Institute of Technology at Kanpur, or IIT-K, have announced a bilateral research partnership to develop enabling technologies that impact future wireless standards. Specifically, InterDigital will sponsor research and innovation at IIT-K that advances MIMO systems to achieve the improved spectrum efficiency and network coverage required for 5G Advanced and 6G network deployments. The InterDigital and IIT-K partnership is aligned with the growing collaboration between India and the United States around 6G research and standardization. The partnership follows a joint statement from the two countries at the recent G20 Summit highlighting the importance of joint research and development in 6G technologies while acknowledging IIT-K as a key collaborator.